<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00862641</url>
  </required_header>
  <id_info>
    <org_study_id>3606-CL-3001</org_study_id>
    <nct_id>NCT00862641</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>A Phase 4, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to determine the safety and tolerance of regadenoson in subjects with
      asthma or chronic obstructive pulmonary disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects Who Had a &gt;15% Decrease in Forced Expiratory Volume in 1 Second (FEV1) at the 2-hour Postbaseline Assessment</measure>
    <time_frame>2 Hours post dose</time_frame>
    <description>FEV1 data was obtained by spirometry measures.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Use of Short-acting Bronchodilators for Treatment of Symptoms After Study Drug Administration</measure>
    <time_frame>Within 2 Hours of study drug administration</time_frame>
    <description>The data represents the numbers of subjects using short acting bronchodilators at time of selected Adverse Event (AE).
Short acting bronchodilators are defined as medications coded to drugs for obstructive airway disease.
The selected respiratory symptomatic AEs included the following preferred terms: dyspnoea, dyspnoea exertional, obstructive airways disorder, tachypnoea, &amp; wheezing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Short-acting Bronchodilators for Treatment of Symptoms After Study Drug Administration</measure>
    <time_frame>Within 24 Hours of study drug administration</time_frame>
    <description>The data represents the numbers of subjects using short acting bronchodilators at time of selected Adverse Event (AE).
Short acting bronchodilators are defined as medications coded to drugs for obstructive airway disease.
The selected respiratory symptomatic AEs included the following preferred terms: dyspnoea, dyspnoea exertional, obstructive airways disorder, tachypnoea, &amp; wheezing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to the 2 Hour Post-dose Assessment for FEV1 Absolute Values</measure>
    <time_frame>Baseline and Hour 2</time_frame>
    <description>FEV1 data was obtained by spirometry measurements.
Change from Baseline is calculated as the Hour 2 measurement minus the Baseline measurement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to the 2 Hour Post-dose Assessment for FEV1 Percent Predicted</measure>
    <time_frame>Baseline and Hour 2</time_frame>
    <description>FEV1 data was obtained by spirometry measurements.
Change from Baseline is calculated as the Hour 2 measurement minus the Baseline measurement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to the 2 Hour Post-dose Assessment for Forced Vital Capacity (FVC)</measure>
    <time_frame>Baseline and Hour 2</time_frame>
    <description>FVC data was obtained by spirometry measurements.
Change from Baseline is calculated as the Hour 2 measurement minus the Baseline measurement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to the 2 Hour Post-dose Assessment for FEV1/ FVC Ratio</measure>
    <time_frame>Baseline and Hour 2</time_frame>
    <description>FEV1 and FVC data was obtained by spirometry measurements.
Change from Baseline is calculated as the Hour 2 measurement minus the Baseline measurement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to the 2 Hour Post-dose Assessment for Oxygen Saturation Measured by Pulse Oximetry</measure>
    <time_frame>Baseline and Hour 2</time_frame>
    <description>Change from Baseline is calculated as the Hour 2 measurement minus the Baseline measurement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Selected Respiratory Adverse Events</measure>
    <time_frame>Within 24 Hours of study drug administration</time_frame>
    <description>The selected respiratory Adverse Events are dyspnoea, dyspnoea exertional, obstructive airways disorder, tachypnoea and wheezing.
Subjects may have reported more than one type of Adverse Event.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1009</enrollment>
  <condition>Asthma</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Placebo - Asthma</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching intravenous (IV) bolus injection, subjects with Asthma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regadenoson - Asthma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.4mg / 5mL intravenous bolus injection, subjects with Asthma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - COPD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regadenoson - COPD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.4mg / 5mL intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regadenoson</intervention_name>
    <description>IV</description>
    <arm_group_label>Regadenoson - Asthma</arm_group_label>
    <arm_group_label>Regadenoson - COPD</arm_group_label>
    <other_name>CVT3146</other_name>
    <other_name>Lexiscan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>IV</description>
    <arm_group_label>Placebo - Asthma</arm_group_label>
    <arm_group_label>Placebo - COPD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has asthma or stable chronic obstructive pulmonary disease (COPD).

          -  Subject has a diagnosis of coronary artery disease (CAD) or risk factors for CAD as
             determined by a current medical diagnosis of at least 2 of the following conditions:
             Type 2 diabetes, hypertension, hypercholesterolemia, current or history of cigarette
             smoking (minimum 10 pack-years exposure) or obesity Body Mass Index (BMI &gt; 30).

          -  Subject must abstain from smoking 3 hours prior and 8 hours post study drug
             administration.

          -  Subject must abstain from any intake of foods and beverages containing a methylated
             xanthine derivative (i.e. caffeine, theobromine, or methylxanthine) within 12 hours
             prior to study drug administration through the Follow-Up visit, as these foods may
             reduce the effects of regadenoson.

          -  Subject is able to safely abstain from theophylline for 12 hours prior to the Day 1
             visit, as determined by the Investigator

          -  Asthma subject's frequency and severity of symptoms have remained unchanged within 30
             days prior to study drug administration

          -  Asthma subject has FEV1 ≥60% predicted

          -  COPD subject has FEV1/FVC &lt; 0.70

        Exclusion Criteria:

          -  Female subject who is pregnant, lactating or of childbearing potential who refuses to
             use a medically acceptable form of contraception until the Follow-Up visit is
             complete.

          -  Subject started on a course of corticosteroids, steroid combination with long-acting
             Beta2-agonist (LABA) (oral or inhaled) or anticholinergic, or has undergone a change
             in dose of such medications ≤ 30 days prior to study drug administration (subject on a
             stable dose of such medications for &gt; 30 days prior to study drug administration is
             allowed).

          -  Subject started leukotriene antagonists (e.g., montelukast), cromones (e.g., cromolyn
             sodium) or 5-lipoxygenase antagonists (e.g. zileuton or zyflo) or has undergone a
             change in dose of medications in these drug classes ≤ 7 days prior to study drug
             administration (subject on a stable dose of these medications for &gt; 7 days prior to
             study drug administration is allowed).

          -  Subject has a history of second or third degree heart block or sinus node dysfunction
             unless the subject has a functioning pacemaker.

          -  Subject has symptomatic hypotension (temporary and reversible conditions that no
             longer exist are allowed).

          -  Subject is allergic or intolerant to aminophylline.

          -  Subject has had a respiratory infection within 2 weeks prior to randomization.

          -  Subject has had surgery within 3 months prior to randomization.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <zip>36117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Deland</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trinity</city>
        <state>Florida</state>
        <zip>34655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Illinois</state>
        <zip>60504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Auburn</city>
        <state>Maine</state>
        <zip>04210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>No. Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55441</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Papillion</city>
        <state>Nebraska</state>
        <zip>68046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brick</city>
        <state>New Jersey</state>
        <zip>08723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chardon</city>
        <state>Ohio</state>
        <zip>44024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Upland</city>
        <state>Pennsylvania</state>
        <zip>19013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Easley</city>
        <state>South Carolina</state>
        <zip>29640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.astellas.us/docs/lexiscan.pdf</url>
    <description>Link to Prescribing information</description>
  </link>
  <results_reference>
    <citation>Prenner BM, Bukofzer S, Behm S, Feaheny K, McNutt BE. A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease. J Nucl Cardiol. 2012 Aug;19(4):681-92. doi: 10.1007/s12350-012-9547-4. Epub 2012 Apr 7.</citation>
    <PMID>22484721</PMID>
  </results_reference>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2009</study_first_submitted>
  <study_first_submitted_qc>March 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2009</study_first_posted>
  <results_first_submitted>November 15, 2010</results_first_submitted>
  <results_first_submitted_qc>November 15, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 15, 2010</results_first_posted>
  <last_update_submitted>September 12, 2012</last_update_submitted>
  <last_update_submitted_qc>September 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>regadenoson</keyword>
  <keyword>CVT 3146</keyword>
  <keyword>asthma</keyword>
  <keyword>coronary artery disease</keyword>
  <keyword>pulmonary disease, chronic obstructive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Regadenoson</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo - Asthma</title>
          <description>Matching intravenous (IV) bolus injection, subjects with Asthma</description>
        </group>
        <group group_id="P2">
          <title>Regadenoson - Asthma</title>
          <description>0.4mg / 5mL intravenous bolus injection, subjects with Asthma</description>
        </group>
        <group group_id="P3">
          <title>Placebo - COPD</title>
          <description>Matching intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)</description>
        </group>
        <group group_id="P4">
          <title>Regadenoson - COPD</title>
          <description>0.4mg / 5mL intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="177"/>
                <participants group_id="P2" count="360"/>
                <participants group_id="P3" count="152"/>
                <participants group_id="P4" count="320"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="176">Completed Population is equal to Safety Analysis Set (SAF)</participants>
                <participants group_id="P2" count="356">Completed Population is equal to Safety Analysis Set (SAF)</participants>
                <participants group_id="P3" count="151">Completed Population is equal to Safety Analysis Set (SAF)</participants>
                <participants group_id="P4" count="316">Completed Population is equal to Safety Analysis Set (SAF)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Randomized, but drug not received</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo - Asthma</title>
          <description>Matching intravenous (IV) bolus injection, subjects with Asthma</description>
        </group>
        <group group_id="B2">
          <title>Regadenoson - Asthma</title>
          <description>0.4mg / 5mL intravenous bolus injection, subjects with Asthma</description>
        </group>
        <group group_id="B3">
          <title>Placebo - COPD</title>
          <description>Matching intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)</description>
        </group>
        <group group_id="B4">
          <title>Regadenoson - COPD</title>
          <description>0.4mg / 5mL intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="176"/>
            <count group_id="B2" value="356"/>
            <count group_id="B3" value="151"/>
            <count group_id="B4" value="316"/>
            <count group_id="B5" value="999"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Between 18 and 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="148"/>
                    <measurement group_id="B2" value="304"/>
                    <measurement group_id="B3" value="95"/>
                    <measurement group_id="B4" value="189"/>
                    <measurement group_id="B5" value="736"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="127"/>
                    <measurement group_id="B5" value="263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="245"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="132"/>
                    <measurement group_id="B5" value="559"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="84"/>
                    <measurement group_id="B4" value="184"/>
                    <measurement group_id="B5" value="440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                    <measurement group_id="B2" value="283"/>
                    <measurement group_id="B3" value="136"/>
                    <measurement group_id="B4" value="284"/>
                    <measurement group_id="B5" value="831"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian - Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Who Had a &gt;15% Decrease in Forced Expiratory Volume in 1 Second (FEV1) at the 2-hour Postbaseline Assessment</title>
        <description>FEV1 data was obtained by spirometry measures.</description>
        <time_frame>2 Hours post dose</time_frame>
        <population>The number of participants analyzed per arm represents Safety Analysis Set (SAF) which included all randomized subjects who received any amount of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Asthma</title>
            <description>Matching intravenous (IV) bolus injection, subjects with Asthma</description>
          </group>
          <group group_id="O2">
            <title>Regadenoson - Asthma</title>
            <description>0.4mg / 5mL intravenous bolus injection, subjects with Asthma</description>
          </group>
          <group group_id="O3">
            <title>Placebo - COPD</title>
            <description>Matching intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)</description>
          </group>
          <group group_id="O4">
            <title>Regadenoson - COPD</title>
            <description>0.4mg / 5mL intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Who Had a &gt;15% Decrease in Forced Expiratory Volume in 1 Second (FEV1) at the 2-hour Postbaseline Assessment</title>
          <description>FEV1 data was obtained by spirometry measures.</description>
          <population>The number of participants analyzed per arm represents Safety Analysis Set (SAF) which included all randomized subjects who received any amount of study drug.</population>
          <units>Percentage of Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="356"/>
                <count group_id="O3" value="151"/>
                <count group_id="O4" value="316"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9"/>
                    <measurement group_id="O2" value="1.1"/>
                    <measurement group_id="O3" value="5.4"/>
                    <measurement group_id="O4" value="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1451</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Analysis of treatment effect was based on the Cochran-Mantel Haenszel(CMH) test stratified by investigative site. Sites with &lt;15 subjects were pooled.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5790</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Analysis of treatment effect was based on the CMH test stratified by investigative site. Sites with less than 15 subjects were pooled.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Short-acting Bronchodilators for Treatment of Symptoms After Study Drug Administration</title>
        <description>The data represents the numbers of subjects using short acting bronchodilators at time of selected Adverse Event (AE).
Short acting bronchodilators are defined as medications coded to drugs for obstructive airway disease.
The selected respiratory symptomatic AEs included the following preferred terms: dyspnoea, dyspnoea exertional, obstructive airways disorder, tachypnoea, &amp; wheezing.</description>
        <time_frame>Within 2 Hours of study drug administration</time_frame>
        <population>The number of participants analyzed per arm represents Safety Analysis Set (SAF) which included all randomized subjects who received any amount of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Asthma</title>
            <description>Matching intravenous (IV) bolus injection, subjects with Asthma</description>
          </group>
          <group group_id="O2">
            <title>Regadenoson - Asthma</title>
            <description>0.4mg / 5mL intravenous bolus injection, subjects with Asthma</description>
          </group>
          <group group_id="O3">
            <title>Placebo - COPD</title>
            <description>Matching intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)</description>
          </group>
          <group group_id="O4">
            <title>Regadenoson - COPD</title>
            <description>0.4mg / 5mL intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Short-acting Bronchodilators for Treatment of Symptoms After Study Drug Administration</title>
          <description>The data represents the numbers of subjects using short acting bronchodilators at time of selected Adverse Event (AE).
Short acting bronchodilators are defined as medications coded to drugs for obstructive airway disease.
The selected respiratory symptomatic AEs included the following preferred terms: dyspnoea, dyspnoea exertional, obstructive airways disorder, tachypnoea, &amp; wheezing.</description>
          <population>The number of participants analyzed per arm represents Safety Analysis Set (SAF) which included all randomized subjects who received any amount of study drug.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="356"/>
                <count group_id="O3" value="151"/>
                <count group_id="O4" value="316"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Short-acting Bronchodilators for Treatment of Symptoms After Study Drug Administration</title>
        <description>The data represents the numbers of subjects using short acting bronchodilators at time of selected Adverse Event (AE).
Short acting bronchodilators are defined as medications coded to drugs for obstructive airway disease.
The selected respiratory symptomatic AEs included the following preferred terms: dyspnoea, dyspnoea exertional, obstructive airways disorder, tachypnoea, &amp; wheezing.</description>
        <time_frame>Within 24 Hours of study drug administration</time_frame>
        <population>The number of participants analyzed per arm represents Safety Analysis Set (SAF) which included all randomized subjects who received any amount of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Asthma</title>
            <description>Matching intravenous (IV) bolus injection, subjects with Asthma</description>
          </group>
          <group group_id="O2">
            <title>Regadenoson - Asthma</title>
            <description>0.4mg / 5mL intravenous bolus injection, subjects with Asthma</description>
          </group>
          <group group_id="O3">
            <title>Placebo - COPD</title>
            <description>Matching intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)</description>
          </group>
          <group group_id="O4">
            <title>Regadenoson - COPD</title>
            <description>0.4mg / 5mL intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Short-acting Bronchodilators for Treatment of Symptoms After Study Drug Administration</title>
          <description>The data represents the numbers of subjects using short acting bronchodilators at time of selected Adverse Event (AE).
Short acting bronchodilators are defined as medications coded to drugs for obstructive airway disease.
The selected respiratory symptomatic AEs included the following preferred terms: dyspnoea, dyspnoea exertional, obstructive airways disorder, tachypnoea, &amp; wheezing.</description>
          <population>The number of participants analyzed per arm represents Safety Analysis Set (SAF) which included all randomized subjects who received any amount of study drug.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="356"/>
                <count group_id="O3" value="151"/>
                <count group_id="O4" value="316"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to the 2 Hour Post-dose Assessment for FEV1 Absolute Values</title>
        <description>FEV1 data was obtained by spirometry measurements.
Change from Baseline is calculated as the Hour 2 measurement minus the Baseline measurement.</description>
        <time_frame>Baseline and Hour 2</time_frame>
        <population>The number of participants analyzed per arm represents Safety Analysis Set (SAF) which included all randomized subjects who received any amount of study drug. The number of participants included in the calculation for each time point is noted in the category titles, as “N”.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Asthma</title>
            <description>Matching intravenous (IV) bolus injection, subjects with Asthma</description>
          </group>
          <group group_id="O2">
            <title>Regadenoson - Asthma</title>
            <description>0.4mg / 5mL intravenous bolus injection, subjects with Asthma</description>
          </group>
          <group group_id="O3">
            <title>Placebo - COPD</title>
            <description>Matching intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)</description>
          </group>
          <group group_id="O4">
            <title>Regadenoson - COPD</title>
            <description>0.4mg / 5mL intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to the 2 Hour Post-dose Assessment for FEV1 Absolute Values</title>
          <description>FEV1 data was obtained by spirometry measurements.
Change from Baseline is calculated as the Hour 2 measurement minus the Baseline measurement.</description>
          <population>The number of participants analyzed per arm represents Safety Analysis Set (SAF) which included all randomized subjects who received any amount of study drug. The number of participants included in the calculation for each time point is noted in the category titles, as “N”.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="356"/>
                <count group_id="O3" value="151"/>
                <count group_id="O4" value="316"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (N=176; 356; 151; 316)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.41" spread="0.689"/>
                    <measurement group_id="O2" value="2.35" spread="0.623"/>
                    <measurement group_id="O3" value="1.70" spread="0.630"/>
                    <measurement group_id="O4" value="1.70" spread="0.655"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 2 (N=174; 351; 147; 313)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.37" spread="0.677"/>
                    <measurement group_id="O2" value="2.33" spread="0.615"/>
                    <measurement group_id="O3" value="1.69" spread="0.651"/>
                    <measurement group_id="O4" value="1.70" spread="0.647"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Hour 2 (N=174; 351; 147; 313)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.160"/>
                    <measurement group_id="O2" value="-0.01" spread="0.129"/>
                    <measurement group_id="O3" value="-0.01" spread="0.152"/>
                    <measurement group_id="O4" value="0.00" spread="0.159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value applies to 'Change at Hour 2'</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0029</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>P-value applies to 'Change at Hour 2'</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6189</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to the 2 Hour Post-dose Assessment for FEV1 Percent Predicted</title>
        <description>FEV1 data was obtained by spirometry measurements.
Change from Baseline is calculated as the Hour 2 measurement minus the Baseline measurement.</description>
        <time_frame>Baseline and Hour 2</time_frame>
        <population>The number of participants analyzed per arm represents Safety Analysis Set (SAF) which included all randomized subjects who received any amount of study drug. The number of participants included in the calculation for each row is noted in the category titles, as “N”.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Asthma</title>
            <description>Matching intravenous (IV) bolus injection, subjects with Asthma</description>
          </group>
          <group group_id="O2">
            <title>Regadenoson - Asthma</title>
            <description>0.4mg / 5mL intravenous bolus injection, subjects with Asthma</description>
          </group>
          <group group_id="O3">
            <title>Placebo - COPD</title>
            <description>Matching intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)</description>
          </group>
          <group group_id="O4">
            <title>Regadenoson - COPD</title>
            <description>0.4mg / 5mL intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to the 2 Hour Post-dose Assessment for FEV1 Percent Predicted</title>
          <description>FEV1 data was obtained by spirometry measurements.
Change from Baseline is calculated as the Hour 2 measurement minus the Baseline measurement.</description>
          <population>The number of participants analyzed per arm represents Safety Analysis Set (SAF) which included all randomized subjects who received any amount of study drug. The number of participants included in the calculation for each row is noted in the category titles, as “N”.</population>
          <units>Percentage of Predicted FEV1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="356"/>
                <count group_id="O3" value="151"/>
                <count group_id="O4" value="316"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (N=176; 356; 151; 316)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.34" spread="13.679"/>
                    <measurement group_id="O2" value="80.32" spread="12.990"/>
                    <measurement group_id="O3" value="55.67" spread="15.131"/>
                    <measurement group_id="O4" value="55.69" spread="16.775"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 2 (N=174; 351; 147; 313)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.91" spread="13.591"/>
                    <measurement group_id="O2" value="80.11" spread="13.324"/>
                    <measurement group_id="O3" value="54.89" spread="15.601"/>
                    <measurement group_id="O4" value="55.61" spread="16.843"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Hour 2 (N=174; 351; 147; 313)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.56" spread="5.368"/>
                    <measurement group_id="O2" value="-0.17" spread="4.519"/>
                    <measurement group_id="O3" value="-0.56" spread="4.846"/>
                    <measurement group_id="O4" value="-0.06" spread="5.170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value applies to 'Change at Hour 2'</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0015</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>P-value applies to 'Change at Hour 2'</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4385</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to the 2 Hour Post-dose Assessment for Forced Vital Capacity (FVC)</title>
        <description>FVC data was obtained by spirometry measurements.
Change from Baseline is calculated as the Hour 2 measurement minus the Baseline measurement.</description>
        <time_frame>Baseline and Hour 2</time_frame>
        <population>The number of participants analyzed per arm represents Safety Analysis Set (SAF) which included all randomized subjects who received any amount of study drug. The number of participants included in the calculation for each row is noted in the category titles, as “N”.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Asthma</title>
            <description>Matching intravenous (IV) bolus injection, subjects with Asthma</description>
          </group>
          <group group_id="O2">
            <title>Regadenoson - Asthma</title>
            <description>0.4mg / 5mL intravenous bolus injection, subjects with Asthma</description>
          </group>
          <group group_id="O3">
            <title>Placebo - COPD</title>
            <description>Matching intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)</description>
          </group>
          <group group_id="O4">
            <title>Regadenoson - COPD</title>
            <description>0.4mg / 5mL intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to the 2 Hour Post-dose Assessment for Forced Vital Capacity (FVC)</title>
          <description>FVC data was obtained by spirometry measurements.
Change from Baseline is calculated as the Hour 2 measurement minus the Baseline measurement.</description>
          <population>The number of participants analyzed per arm represents Safety Analysis Set (SAF) which included all randomized subjects who received any amount of study drug. The number of participants included in the calculation for each row is noted in the category titles, as “N”.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="356"/>
                <count group_id="O3" value="151"/>
                <count group_id="O4" value="316"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (N=176; 356; 151; 316)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.22" spread="0.883"/>
                    <measurement group_id="O2" value="3.16" spread="0.829"/>
                    <measurement group_id="O3" value="2.75" spread="0.833"/>
                    <measurement group_id="O4" value="2.83" spread="0.889"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 2 (N=174; 351; 147; 313)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.17" spread="0.887"/>
                    <measurement group_id="O2" value="3.11" spread="0.809"/>
                    <measurement group_id="O3" value="2.70" spread="0.856"/>
                    <measurement group_id="O4" value="2.84" spread="0.857"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Hour 2 (N=174; 351; 147; 313)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.208"/>
                    <measurement group_id="O2" value="-0.03" spread="0.168"/>
                    <measurement group_id="O3" value="-0.04" spread="0.230"/>
                    <measurement group_id="O4" value="0.00" spread="0.239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value applies to 'Change at Hour 2'</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0789</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>P-value applies to 'Change at Hour 2'</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0258</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to the 2 Hour Post-dose Assessment for FEV1/ FVC Ratio</title>
        <description>FEV1 and FVC data was obtained by spirometry measurements.
Change from Baseline is calculated as the Hour 2 measurement minus the Baseline measurement.</description>
        <time_frame>Baseline and Hour 2</time_frame>
        <population>The number of participants analyzed per arm represents Safety Analysis Set (SAF) which included all randomized subjects who received any amount of study drug. The number of participants included in the calculation for each row is noted in the category titles, as &quot;N&quot;.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Asthma</title>
            <description>Matching intravenous (IV) bolus injection, subjects with Asthma</description>
          </group>
          <group group_id="O2">
            <title>Regadenoson - Asthma</title>
            <description>0.4mg / 5mL intravenous bolus injection, subjects with Asthma</description>
          </group>
          <group group_id="O3">
            <title>Placebo - COPD</title>
            <description>Matching intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)</description>
          </group>
          <group group_id="O4">
            <title>Regadenoson - COPD</title>
            <description>0.4mg / 5mL intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to the 2 Hour Post-dose Assessment for FEV1/ FVC Ratio</title>
          <description>FEV1 and FVC data was obtained by spirometry measurements.
Change from Baseline is calculated as the Hour 2 measurement minus the Baseline measurement.</description>
          <population>The number of participants analyzed per arm represents Safety Analysis Set (SAF) which included all randomized subjects who received any amount of study drug. The number of participants included in the calculation for each row is noted in the category titles, as &quot;N&quot;.</population>
          <units>Percentage of FEV1 / FVC</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="356"/>
                <count group_id="O3" value="151"/>
                <count group_id="O4" value="316"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (N=176; 356; 151; 316)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.88" spread="7.510"/>
                    <measurement group_id="O2" value="74.59" spread="7.084"/>
                    <measurement group_id="O3" value="61.95" spread="12.684"/>
                    <measurement group_id="O4" value="60.00" spread="13.191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 2 ( N=174; 351; 147; 313)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.11" spread="7.898"/>
                    <measurement group_id="O2" value="75.09" spread="7.074"/>
                    <measurement group_id="O3" value="62.26" spread="12.907"/>
                    <measurement group_id="O4" value="59.72" spread="13.171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Hour 2 (N=174; 351; 147; 313)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="3.329"/>
                    <measurement group_id="O2" value="0.52" spread="2.562"/>
                    <measurement group_id="O3" value="0.31" spread="3.177"/>
                    <measurement group_id="O4" value="-0.30" spread="3.571"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value applies to 'Change at Hour 2'</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2087</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>P-value applies to 'Change at Hour 2'</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0289</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to the 2 Hour Post-dose Assessment for Oxygen Saturation Measured by Pulse Oximetry</title>
        <description>Change from Baseline is calculated as the Hour 2 measurement minus the Baseline measurement.</description>
        <time_frame>Baseline and Hour 2</time_frame>
        <population>The number of participants analyzed per arm represents Safety Analysis Set (SAF) which included all randomized subjects who received any amount of study drug. The number of participants included in the calculation for each row is noted in the category titles, as “N”.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Asthma</title>
            <description>Matching intravenous (IV) bolus injection, subjects with Asthma</description>
          </group>
          <group group_id="O2">
            <title>Regadenoson - Asthma</title>
            <description>0.4mg / 5mL intravenous bolus injection, subjects with Asthma</description>
          </group>
          <group group_id="O3">
            <title>Placebo - COPD</title>
            <description>Matching intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)</description>
          </group>
          <group group_id="O4">
            <title>Regadenoson - COPD</title>
            <description>0.4mg / 5mL intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to the 2 Hour Post-dose Assessment for Oxygen Saturation Measured by Pulse Oximetry</title>
          <description>Change from Baseline is calculated as the Hour 2 measurement minus the Baseline measurement.</description>
          <population>The number of participants analyzed per arm represents Safety Analysis Set (SAF) which included all randomized subjects who received any amount of study drug. The number of participants included in the calculation for each row is noted in the category titles, as “N”.</population>
          <units>Percentage of Oxygen Saturation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="356"/>
                <count group_id="O3" value="151"/>
                <count group_id="O4" value="316"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (N=170; 350; 143; 302)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.3" spread="1.81"/>
                    <measurement group_id="O2" value="96.3" spread="1.81"/>
                    <measurement group_id="O3" value="94.7" spread="2.40"/>
                    <measurement group_id="O4" value="95.0" spread="2.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 2 (N=170; 349; 143; 299)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.9" spread="1.80"/>
                    <measurement group_id="O2" value="96.0" spread="1.78"/>
                    <measurement group_id="O3" value="94.2" spread="2.25"/>
                    <measurement group_id="O4" value="94.5" spread="2.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Hour 2 (N=170; 349; 143; 299)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="1.47"/>
                    <measurement group_id="O2" value="-0.4" spread="1.35"/>
                    <measurement group_id="O3" value="-0.4" spread="1.42"/>
                    <measurement group_id="O4" value="-0.5" spread="1.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value applies to 'Change at Hour 2'
P-value based on ranked analysis of covariance with treatment and investigator site as main effects and baseline value as a covariate in the model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9904</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>P-value applies to 'Change at Hour 2'
P-value based on ranked analysis of covariance with treatment and investigator site as main effects and baseline value as a covariate in the model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8085</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Selected Respiratory Adverse Events</title>
        <description>The selected respiratory Adverse Events are dyspnoea, dyspnoea exertional, obstructive airways disorder, tachypnoea and wheezing.
Subjects may have reported more than one type of Adverse Event.</description>
        <time_frame>Within 24 Hours of study drug administration</time_frame>
        <population>The number of participants analyzed per arm represents Safety Analysis Set (SAF) which included all randomized subjects who received any amount of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Asthma</title>
            <description>Matching intravenous (IV) bolus injection, subjects with Asthma</description>
          </group>
          <group group_id="O2">
            <title>Regadenoson - Asthma</title>
            <description>0.4mg / 5mL intravenous bolus injection, subjects with Asthma</description>
          </group>
          <group group_id="O3">
            <title>Placebo - COPD</title>
            <description>Matching intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)</description>
          </group>
          <group group_id="O4">
            <title>Regadenoson - COPD</title>
            <description>0.4mg / 5mL intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Selected Respiratory Adverse Events</title>
          <description>The selected respiratory Adverse Events are dyspnoea, dyspnoea exertional, obstructive airways disorder, tachypnoea and wheezing.
Subjects may have reported more than one type of Adverse Event.</description>
          <population>The number of participants analyzed per arm represents Safety Analysis Set (SAF) which included all randomized subjects who received any amount of study drug.</population>
          <units>Percentage of Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="356"/>
                <count group_id="O3" value="151"/>
                <count group_id="O4" value="316"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dyspnoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="10.7"/>
                    <measurement group_id="O3" value="2.6"/>
                    <measurement group_id="O4" value="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wheezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="3.1"/>
                    <measurement group_id="O3" value="0.7"/>
                    <measurement group_id="O4" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Obstructive Airways Disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea Exertional</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0.7"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tachypnoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Event collection began immediately following study drug administration through the follow-up visit. Serious Adverse Events occurring until 30 days after dosing were reported.</time_frame>
      <desc>Treatment Emergent Adverse Events were defined as Adverse Events starting or worsening after starting administration of the test drug.
Within a system organ class subjects may have reported more than one type of Adverse Event.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo - Asthma</title>
          <description>Matching intravenous (IV) bolus injection, subjects with Asthma</description>
        </group>
        <group group_id="E2">
          <title>Regadenoson - Asthma</title>
          <description>0.4mg / 5mL intravenous bolus injection, subjects with Asthma</description>
        </group>
        <group group_id="E3">
          <title>Placebo - COPD</title>
          <description>Matching intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)</description>
        </group>
        <group group_id="E4">
          <title>Regadenoson - COPD</title>
          <description>0.4mg / 5mL intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="356"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <description>SAE was reported after the follow-up visit.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram change</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amyotrophic lateral sclerosis</sub_title>
                <description>SAE was reported after the follow-up visit.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="212" subjects_at_risk="356"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="177" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="356"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="356"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="356"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="356"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="356"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="356"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="356"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="62" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="356"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="45" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="356"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="356"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="57" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="356"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site’s manuscript at least 30 days prior to publication to ensure that no confidential information of Sponsor is included in the document. Sponsor may delay the publication for an additional 60 days to seek patent protection.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Medical Director, Medical Affairs</name_or_title>
      <organization>Astellas Pharma Global Development</organization>
      <email>clinicaltrials@us.astellas.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

